Clinical trial CTIS2024-520287-34-01
Status: Recruiting (according to the registry)Phase 1/2/3/4Latest change: Source: CTIS (European Union) (via WHO ICTRP)
What's on this page?
Information in the record
Original title: A phase II randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of an oral solution of 9-? tetrahydrocannabinol/cannabidiol (THC/CBD) in multiple sclerosis patients with chronic neuropathic pain
- Record number
- CTIS2024-520287-34-01
- Registry
- CTIS (European Union) (via WHO ICTRP)
- Status
- Recruiting (according to the registry)
- Type and phase
- Clinical trial, phase 1/2/3/4
- Participants
- Target: 68
- Condition (as registered)
- Chronic neuropathic pain due to multiple sclerosis (MS), MedDRA version: 21.0Level: LLTClassification code: 10054095Term: Neuropathic pain Class: 10029205, Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Countries
- Portugal
- Topic in the guide
- Neuropathic Pain, MS Spasticity
Timeline
According to the CTIS (European Union) (via WHO ICTRP) record. Future dates are the investigator’s estimates and may change.
- Registration: March 27, 2025
History
We check the record once a month via WHO ICTRP; here are the changes we have seen since we started tracking it, newest first.
- : Added to tracking. Status: Recruiting.
Results
No results have been published yet. When they are, they will appear here. A trial being under way does not mean CBD works for this condition; only the results can show that.
All ongoing trials · Neuropathic Pain: guide page · MS Spasticity: guide page · Thinking of taking part? Which specialist to see